These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 9816175

  • 1. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM.
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 3. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C, García-Pérez MJ, Ramirez R, Martín C, Alvarez MA, Martinez F, Gómez P, García-Castellano JM, Torres A.
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [Abstract] [Full Text] [Related]

  • 4. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ, Malya R, Rawat A.
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [Abstract] [Full Text] [Related]

  • 6. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
    Lissoni P, Mengo S, Bucovec R, Brivio F, Fumagalli L, Tancini G, Gardani GS.
    In Vivo; 2003 Jun; 17(1):73-5. PubMed ID: 12655794
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA.
    Cancer Res; 1991 Jul 15; 51(14):3669-76. PubMed ID: 1648441
    [Abstract] [Full Text] [Related]

  • 10. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM, Padavic-Shaller K, Kitson J, Watts P, Krigel RL, Litwin S.
    Cancer Res; 1991 Aug 01; 51(15):3910-8. PubMed ID: 1906779
    [Abstract] [Full Text] [Related]

  • 11. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM.
    Cancer; 2000 Mar 15; 88(6):1317-24. PubMed ID: 10717612
    [Abstract] [Full Text] [Related]

  • 12. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
    Hank JA, Albertini M, Wesly OH, Schiller JH, Borchert A, Moore K, Bechhofer R, Storer B, Gan J, Gambacorti C.
    Clin Cancer Res; 1995 May 15; 1(5):481-91. PubMed ID: 9816007
    [Abstract] [Full Text] [Related]

  • 13. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender J.
    Bone Marrow Transplant; 1995 Nov 15; 16(5):655-61. PubMed ID: 8547862
    [Abstract] [Full Text] [Related]

  • 14. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM.
    Clin Cancer Res; 2001 May 15; 7(5):1181-91. PubMed ID: 11350882
    [Abstract] [Full Text] [Related]

  • 15. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M.
    Haematologica; 2001 Jan 15; 86(1):44-51. PubMed ID: 11146570
    [Abstract] [Full Text] [Related]

  • 16. Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores decreased monocyte HLA-DR expression after cardiopulmonary bypass.
    Börgermann J, Friedrich I, Scheubel R, Kuss O, Lendemans S, Silber RE, Kreuzfelder E, Flohé S.
    Thorac Cardiovasc Surg; 2007 Feb 15; 55(1):24-31. PubMed ID: 17285470
    [Abstract] [Full Text] [Related]

  • 17. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
    Schmidinger M, Steger G, Wenzel C, Locker GJ, Budinsky AC, Brodowicz T, Kramer G, Marberger M, Zielinski CC, Austrian Renal Cell Carcinoma Study Group.
    J Immunother; 2001 Feb 15; 24(3):257-62. PubMed ID: 11394504
    [Abstract] [Full Text] [Related]

  • 18. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
    Lendemans S, Kreuzfelder E, Waydhas C, Schade FU, Flohé S.
    Inflamm Res; 2007 Jan 15; 56(1):38-44. PubMed ID: 17334669
    [Abstract] [Full Text] [Related]

  • 19. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
    Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA, Sondel PM.
    Clin Cancer Res; 1997 Aug 15; 3(8):1277-88. PubMed ID: 9815810
    [Abstract] [Full Text] [Related]

  • 20. Upregulation of HLA class II, but not intercellular adhesion molecule 1 (ICAM-1) by granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-3 (IL-3) in synergy with dexamethasone.
    Sadeghi R, Feldmann M, Hawrylowicz C.
    Eur Cytokine Netw; 1992 Aug 15; 3(4):373-80. PubMed ID: 1358241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.